AC
PDLI

Ascend Capital’s PDL BioPharma, Inc. PDLI Stock Holding History

Ascend Capital’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-100,000
Closed -$335K – 197
2016
Q3 		$335K Buy
+100,000
New +$317K 0.02% 115

Other funds holding PDLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ascend Capital's PDLI Position: Q4 2016 in Review

Ascend Capital sold out of PDL BioPharma, Inc. (PDLI) in Q4 2016, closing a stake of 100,000 shares — an estimated $335K sold.

Ascend Capital first reported a position in PDLI in Q3 2016 and held it in 1 quarter. The position peaked at $335K in Q3 2016. 190 funds tracked by Wall St. Rank hold PDLI as of Q4 2016.

  • Ascend Capital reported no remaining PDL BioPharma, Inc. position as of Q4 2016 after selling out during the quarter.
  • Ascend Capital sold 100,000 PDL BioPharma, Inc. shares in Q4 2016, an estimated $335K.
  • Ascend Capital first reported a position in PDL BioPharma, Inc. in Q3 2016 and held it in 1 quarter.
  • Ascend Capital's PDL BioPharma, Inc. position peaked at $335K in Q3 2016.
  • 190 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2016.

Based on Ascend Capital's 13F filing for Q4 2016, filed 13 Feb 2017.